Nationwide in-hospital mortality following colonic cancer resection according to hospital volume in Germany

被引:38
作者
Diers, J. [1 ,2 ]
Wagner, J. [1 ]
Baum, P. [1 ]
Lichthardtl, S. [1 ]
Kastnerl, C. [1 ]
Matthes, N. [1 ,4 ]
Loeb, S. [1 ]
Matthes, H. [2 ]
Germer, C-T [1 ,3 ]
Wiegering, A. [1 ,3 ,4 ]
机构
[1] Univ Wurzburg, Dept Gen Visceral Vasc & Paediat Surg, Wurzburg, Germany
[2] Univ Wurzburg, Med Ctr, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany
[3] Univ Wurzburg, Dept Biochem & Mol Biol, Wurzburg, Germany
[4] Havelhohe Community Hosp, Berlin, Germany
来源
BJS OPEN | 2019年 / 3卷 / 05期
关键词
COMPLETE MESOCOLIC EXCISION; ADJUVANT TREATMENT; STAGE-II; SURGERY; SURVIVAL; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; OUTCOMES;
D O I
10.1002/bjs5.50173
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Colonic cancer is the most common cancer of the gastrointestinal tract. The aim of this study was to determine mortality rates following colonic cancer resection and the effect of hospital caseload on in-hospital mortality in Germany. Methods Patients admitted with a diagnosis of colonic cancer undergoing colonic resection from 2012 to 2015 were identified from a nationwide registry using procedure codes. The outcome measure was in-hospital mortality. Hospitals were ranked according to their caseload for colonic cancer resection, and patients were categorized into five subgroups on the basis of hospital volume. Results Some 129 196 colonic cancer resections were reviewed. The overall in-house mortality rate was 5 center dot 8 per cent, ranging from 6 center dot 9 per cent (1775 of 25 657 patients) in very low-volume hospitals to 4 center dot 8 per cent (1239 of 25 825) in very high-volume centres (P < 0 center dot 001). In multivariable logistic regression analysis the risk-adjusted odds ratio for in-house mortality was 0 center dot 75 (95 per cent c.i. 0 center dot 66 to 0 center dot 84) in very high-volume hospitals performing a mean of 85 center dot 0 interventions per year, compared with that in very low-volume hospitals performing a mean of only 12 center dot 7 interventions annually, after adjustment for sex, age, co-morbidity, emergency procedures, prolonged mechanical ventilation and transfusion. Conclusion In Germany, patients undergoing colonic cancer resections in high-volume hospitals had with improved outcomes compared with patients treated in low-volume hospitals.
引用
收藏
页码:672 / 677
页数:6
相关论文
共 17 条
  • [1] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    Andre, T
    Boni, C
    Mounedji-Boudiaf, L
    Navarro, M
    Tabernero, J
    Hickish, T
    Topham, C
    Zaninelli, M
    Clingan, P
    Bridgewater, J
    Tabah-Fisch, I
    de Gramont, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) : 2343 - 2351
  • [2] Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study
    Andre, Thierry
    de Gramont, Armand
    Vernerey, Dewi
    Chibaudel, Benoist
    Bonnetain, Franck
    Tijeras-Raballand, Annemilai
    Scriva, Aurelie
    Hickish, Tamas
    Tabernero, Josep
    Van Laethem, Jean Luc
    Banzi, Maria
    Maartense, Eduard
    Shmueli, Einat
    Carlsson, Goran U.
    Scheithauer, Werner
    Papamichael, Demetris
    Moeehler, Marcus
    Landolfi, Stefania
    Demetter, Pieter
    Colote, Soudhir
    Tournigand, Christophe
    Louvet, Christophe
    Duval, Alex
    Flejou, Jean-Francois
    de Gramont, Aimery
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (35) : 4176 - +
  • [3] Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
    Andre, Thierry
    Boni, Corrado
    Navarro, Matilde
    Tabernero, Josep
    Hickish, Tamas
    Topham, Clare
    Bonetti, Andrea
    Clingan, Philip
    Bridgewater, John
    Rivera, Fernando
    de Gramont, Aimery
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3109 - 3116
  • [4] [Anonymous], 19 INF TUM KLIN EP K
  • [5] [Anonymous], KLASS TERM STAND GES
  • [6] [Anonymous], DAT SUPPL DIAGN REL
  • [7] Workload and surgeon's specialty for outcome after colorectal cancer surgery
    Archampong, David
    Borowski, David
    Wille-Jorgensen, Peer
    Iversen, Lene H.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (03):
  • [8] Short-term outcomes after complete mesocolic excision compared with "conventional' colonic cancer surgery
    Bertelsen, C. A.
    Neuenschwander, A. U.
    Jansen, J. E.
    Kirkegaard-Klitbo, A.
    Tenma, J. R.
    Wilhelmsen, M.
    Rasmussen, L. A.
    Jepsen, L. V.
    Kristensen, B.
    Goegenur, I.
    [J]. BRITISH JOURNAL OF SURGERY, 2016, 103 (05) : 581 - 589
  • [9] Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: a retrospective, population-based study
    Bertelsen, Claus Anders
    Neuenschwander, Anders Ulrich
    Jansen, Jens Erik
    Wilhelmsen, Michael
    Kirkegaard-Klitbo, Anders
    Tenma, Jutaka Reilin
    Bols, Birgitte
    Ingeholm, Peter
    Rasmussen, Leif Ahrenst
    Jepsen, Lars Vedel
    Iversen, Else Refsgaard
    Kristensen, Bent
    Gogenur, Ismail
    [J]. LANCET ONCOLOGY, 2015, 16 (02) : 161 - 168
  • [10] Bonjer HJ, 2009, LANCET ONCOL, V10, P44, DOI 10.1016/S1470-2045(08)70310-3